Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseinterventionalRules rewrite
Not a traditional drug phase: Air filtration systems without filters (sham) for Cardiovascular (CV) Risk
Obesity and exposure to fine particulate matter (particles of aerodynamic diameter less than 2.5 µm, PM2.5) air pollution are established risk factors for cardiovascular (CV) morbidity and mortality. This proposed pilot project seeks to assess interactions between PM2.5 exposure, obesity, CV health, and dietary antioxidant in subjects with obesity.
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Air filtration systems without filters (sham). The registry lists allocation as randomized. Obesity and exposure to fine particulate matter (particles of aerodynamic diameter less than 2.5 µm, PM2.5) air pollution are established risk factors for cardiovascular (CV) morbidity and mortality.
They plan to enroll about 20 people at East Lansing. Taking part typically means using or being fitted with a device plus check-ins.
Official title (unrewritten)
Investigating Interactions Between PM2.5 Exposure, Obesity, Cardiovascular Health and Dietary Antioxidant in Subjects With Obesity
Interventions: Air filtration systems without filters (sham)
any CV event (myocardial infarction, stroke, heart failure) in the past 3 months
unstable CV condition (class 3-4 angina or heart failure) or any medical condition that would place the subject at risk from participation or jeopardize study integrity (per investigators)
expected overnight travel outside their home during the 9-week study period
lung disease requiring oxygen
cancer receiving active treatment or chemotherapy
CPAP use for sleep apnea
CV medication change in the prior month
Contact
No central phone on the registry card. Use the official listing to reach a site.
Sites listed on ClinicalTrials.gov
1 listed
Michigan State University — East Lansing, Michigan (recruiting)
Related recruiting trials in this snapshot
RecruitingNot a traditional drug phaseSioux Falls, South Dakota
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research. Individuals affected by rare diseases, undiagnosed conditions, and disorders of unknown prevalence may voluntarily contribute health information to support natural history studies, participant recruitment, and other research efforts.
The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the liver.
Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH).
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07924839?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07924839?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.